2023
DOI: 10.1016/j.microc.2023.108827
|View full text |Cite
|
Sign up to set email alerts
|

Recent advances in assembly strategies of new advanced materials-based analytical methods for the detection of cardiac biomarkers as a diagnosis tool

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 122 publications
0
2
0
Order By: Relevance
“…Acute myocardial infarction (AMI) is a serious cardiovascular disease and a main cause of human death globally. According to the existing methods, the detection of cardiac biomarkers is the most effective strategy for early AMI diagnosis. Potential biomarkers with high feasibility are cardiac troponin I (cTnI), creatine kinase-MB isoenzymes (CK-MB), and heart-type fatty acid-binding protein (H-FABP), which are large molecular proteins in body fluids. Despite cTnI being the “gold standard” for AMI diagnosis, its early-stage sensitivity is suboptimal. Alternatively, H-FABP can be rapidly released into the blood when the myocardium is damaged, making it an ideal early-stage AMI marker with high sensitivity and specificity. ,,, At present, various practicable methods are investigated to detect H-FABP, including lateral flow immunoassay, photoelectrochemical, fluorescence (FL) analysis, and electrochemical methods . However, these methods have some limitations, such as cumbersome procedures and a long operating time. Consequently, there is a critical need for a convenient and accurate method to detect H-FABP in clinical settings.…”
Section: Introductionmentioning
confidence: 99%
“…Acute myocardial infarction (AMI) is a serious cardiovascular disease and a main cause of human death globally. According to the existing methods, the detection of cardiac biomarkers is the most effective strategy for early AMI diagnosis. Potential biomarkers with high feasibility are cardiac troponin I (cTnI), creatine kinase-MB isoenzymes (CK-MB), and heart-type fatty acid-binding protein (H-FABP), which are large molecular proteins in body fluids. Despite cTnI being the “gold standard” for AMI diagnosis, its early-stage sensitivity is suboptimal. Alternatively, H-FABP can be rapidly released into the blood when the myocardium is damaged, making it an ideal early-stage AMI marker with high sensitivity and specificity. ,,, At present, various practicable methods are investigated to detect H-FABP, including lateral flow immunoassay, photoelectrochemical, fluorescence (FL) analysis, and electrochemical methods . However, these methods have some limitations, such as cumbersome procedures and a long operating time. Consequently, there is a critical need for a convenient and accurate method to detect H-FABP in clinical settings.…”
Section: Introductionmentioning
confidence: 99%
“…As a result, it becomes vital to develop an accurate and reliable method and/or platform for the early diagnosis of AMI. Developing such a platform/method will profoundly impact the medical diagnosis of AMI and the timely prevention of AMI [3][4][5][6][7][8] . It is well known that at the onset of AMI or within a few hours of AMI, a tiny (approx.…”
Section: Introductionmentioning
confidence: 99%